Profile of lebrikizumab and its potential in the treatment of asthma

Diego Jose Maselli¹
Holly Keyt¹
Linda Rogers²

¹Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Pulmonary, Critical Care, and Sleep Medicine Division, Mount Sinai-National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Abstract: Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Periostin, an extracellular protein, has been used as a surrogate marker of IL-13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis. Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile. Other therapies that target IL-13 and the receptor of IL-4/IL-13 have been studied, but future studies are needed to determine their role in the treatment of asthma.

Keywords: asthma, severe asthma, lebrikizumab, IL-13, periostin

Introduction

Patients with refractory asthma account for approximately 5%–10% of all patients with asthma, but these experience significant impairment, poorer outcomes, and consume greater resources than mild-to-moderate asthmatics.¹⁻³ For these reasons, novel asthma therapies are needed.

Phenotypic characterization of asthma patients has led to great advances in the “personalization” of treatment.⁴ With the aid of biomarkers, patients can receive targeted therapy, thus potentially yielding improved outcomes. An example of this approach is the use of omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE). In patients with allergic asthma and IgE production against perennial allergens, omalizumab has been shown to decrease exacerbations, reduce steroid requirements, reduce hospitalizations, and improve quality of life.⁵⁻⁶ Mepolizumab, a humanized monoclonal antibody that targets interleukin (IL)-5, also has shown potential in improving asthma symptoms, exacerbation rates, and need for corticosteroids in asthmatics with an eosinophilic inflammatory profile.⁷⁻⁸ Despite some patients showing improved asthma outcomes, others fail to respond to these therapies, revealing a need for other options. IL-13 has been shown to be a central mediator in T helper cell type 2 (Th2) inflammatory response and has a prominent role in the pathophysiology of asthma.⁹⁻¹⁰ In this article, we review lebrikizumab, a monoclonal antibody targeting IL-13 and showing early promise for the treatment of asthma. Studies and reports were identified from the databases of PubMed/medline and ClinicalTrials.gov from the US National Institutes of Health and the Cochrane Register of Controlled Trials. The search was
performed using the combined keywords lebrikizumab or anti-IL-13 or IL-13 blockage or IL-13 antibody with asthma. No language or date restrictions were used.

**IL-13**

IL-13 has been linked to multiple inflammatory features of asthma. In the airways, IL-13 increases the migration and survival of eosinophils, activates macrophages, and increases the production of mucus by inducing goblet cell hyperplasia. With regard to immunoglobulin production, both IL-13 and the related cytokine IL-4 are key requirements for the class switch to IgE production by B cells. IL-13 has been associated with increased subepithelial collagen deposition through activation of fibroblasts. This process may be mediated by activation of IL-13Rα2 and induction of transforming growth factor-beta. Impact on these particular pathways suggests the potential for both anti-inflammatory and possible airway remodeling effects, making IL-13 an attractive cytokine to target for treatment of severe asthma.

**Periostin**

Periostin, previously known as osteoblast-specific factor 2, is an extracellular protein that is expressed in multiple cellular lines. Periostin expression is augmented during skeletal fracture or stress and our initial understanding of it was in relation to its role in bone development and remodeling. Comprehensive studies of IL-13-inducible genes in human bronchial epithelial cells found that periostin was highly expressed. In pulmonary fibroblasts and bronchial epithelial cells, its expression is also induced by IL-4 in a similar intensity to IL-13. The role of periostin has only been partially elucidated in asthma. It has been linked to airway subepithelial fibrosis through activation of transforming growth factor-beta as well as through activation of fibroblasts, leading to increased collagen deposition. It is a ligand for integrin receptors and supports adhesion and migration of epithelial cells. Immunohistochemical assays in subjects with asthma have demonstrated that periostin is concentrated in the epithelial basement membrane. Genome-wide profiling has confirmed the role of periostin as part of the Th2-driven inflammatory response in asthma.

Periostin is a more stable surrogate of Th2 inflammation than IL-13, which is unstable and difficult to measure. Periostin likely moves easily from the affected tissues to the vessels. Additionally, basal levels are low, approximately 50 ng/mL, compared to other serum proteins; so, increased production may be easily detected. These unique properties make periostin a very attractive serum biomarker to study targeted therapies in patients with Th2-type inflammation, more specifically, to identify those with high IL-13 activity. Periostin is currently undergoing validation as a serum marker of Th2-driven inflammation in asthma.

**Lebrikizumab**

Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies of IL-13 performed in heterogeneous asthma populations have shown mixed results (Table 1). A study by Corren et al evaluated the use of lebrikizumab in uncontrolled asthmatics despite the use of inhaled corticosteroids (ICS). The study was a Phase II, double-blind, placebo-controlled trial that included 219 adults. All of the patients used ICS and the majority (80%) used a long-acting beta agonist (LABA). Before randomization, the patients were classified as having a high or low “Th2” status based on IgE levels and peripheral blood eosinophil counts. This grouping was performed to equally balance the surrogate markers of IL-13. The patients were then randomized using a dynamic scheme following a 1:1 ratio with regard to “Th2” status. Additionally, all patients had their baseline periostin level measured. The patients received 250 mg of lebrikizumab or placebo subcutaneously monthly for 6 months. At Week 12, the mean increase in forced expiratory volume in 1 second (FEV1) was 5.5% higher in the treatment group compared to that in the placebo group (9.8%±1.9% vs 4.3%±1.5%; P=0.02). In patients with a high periostin level, FEV1 was higher by 8.2% in the lebrikizumab group compared to the value in the placebo group (14.0%±3.1% vs 5.8%±2.1%; P=0.03). Patients with a low periostin level who received lebrikizumab had no significant improvement in FEV1. Between the two groups, there was no significant difference in quality of life or exacerbation rates. However, the high “Th2” subgroup of patients who received lebrikizumab had a 60% decrease in exacerbation rates compared to the placebo group. The patients who received lebrikizumab had a 19% mean decrease in fractional exhaled nitric oxide (FeNO) levels compared to an increase of 10% in the placebo group at the end of the study. Importantly, the improvement of FeNO levels was more pronounced in the high-periostin subgroup compared to the low-periostin subgroup (34% vs 4.3%, respectively). Patients with high FeNO levels also had greater improvement in lung function and fewer exacerbations.

This study has important implications. The FEV1 improvements were modest in patients who received lebrikizumab; however, a greater improvement was seen in those with surrogate markers of Th2-driven inflammation. The study suggests that eosinophil counts, IgE levels, FeNO,
and periostin could potentially be used to predict which patients would benefit from treatment with lebrikizumab. Additionally, the effects on FEV$_1$ were seen relatively early in the course of treatment, suggesting that the inhibition of IL-13 has a rapid effect.

Noonan et al$^{23}$ tested lebrikizumab in mild asthmatics in a Phase II, randomized, placebo-controlled, double-blind study. Lebrikizumab in three different doses (125 mg, 250 mg, or 500 mg administered subcutaneously) or placebo were given monthly for 3 months to 212 patients with asthma not using ICS. The primary efficacy end point was the relative change in FEV$_1$. The investigators found no significant difference, either statistically or clinically, in FEV$_1$ among the groups. However, the lebrikizumab treatment groups had a reduction in the rate of protocol-defined treatment failure compared to the placebo group. Moreover, the treatment groups had a reduction in FeNO levels, suggesting positive effect. Despite these encouraging observations, the primary efficacy end point findings are not consistent with the study by Corren et al,$^{24}$ suggesting that the severity of asthma, and possibly steroid resistance, may influence the response to lebrikizumab.

Another study recently explored the efficacy of lebrikizumab in patients with mild asthma who underwent airway allergen challenge.$^{26}$ This technique consists of administering doubling doses of a standardized extract of an allergen to which the patients previously had a positive skin response. The dose of the extract that induced a $\geq 20\%$ reduction in FEV$_1$ in the early asthmatic response (5–30 minutes) is recorded. During the second part of the airway challenge, the dose previously recorded is readministered at a later time point (typically weeks) to test a therapy for asthma. The responses to the allergen challenge before and after a therapy being evaluated for asthma are then compared. Airway allergen challenge testing has limitations, as it may be influenced by infections, exposure to other allergens, and the inherent variability of FEV$_1$ in asthmatics, but it has been validated to evaluate effects of treatments in asthma.$^{27,28}$

The study evaluating lebrikizumab was a Phase II, randomized, double-blind, parallel-group study that included 29 subjects.$^{26}$ Patients who received lebrikizumab had a reduction of 48% in exacerbation rates in asthmatics, but it has been validated to evaluate effects of treatments in asthma.$^{27,28}$ The study evaluating lebrikizumab was a Phase II, randomized, double-blind, parallel-group study that included 29 subjects.$^{26}$

The study evaluating lebrikizumab was a Phase II, randomized, double-blind, parallel-group study that included 29 subjects.$^{26}$ Patients who received lebrikizumab had a reduction of 48% in exacerbation rates in asthmatics, but it has been validated to evaluate effects of treatments in asthma.$^{27,28}$ The study evaluating lebrikizumab was a Phase II, randomized, double-blind, parallel-group study that included 29 subjects.$^{26}$ Patients who received lebrikizumab had a reduction of 48% in exacerbation rates in asthmatics, but it has been validated to evaluate effects of treatments in asthma.$^{27,28}$

**Table I.** Studies of lebrikizumab in asthma

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Number of patients</th>
<th>Population</th>
<th>Regimen</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corren et al (2011)$^{24}$</td>
<td>Randomized, double-blind, multicenter</td>
<td>219</td>
<td>Uncontrolled asthmatics despite ICS, 80% using LABA</td>
<td>Lebrikizumab 250 mg SQ monthly for 6 months or placebo</td>
<td>Overall improvement of pulmonary function; response was more pronounced in patients with high periostin levels. Patients with a Th2 inflammatory profile had a decrease in exacerbation rates</td>
</tr>
<tr>
<td>Noonan et al (2013)$^{25}$</td>
<td>Randomized, double-blind</td>
<td>212</td>
<td>Mild asthmatics not using ICS</td>
<td>Lebrikizumab 125 mg, 250 mg, 500 mg, or placebo SQ monthly for 3 months</td>
<td>No significant difference in the FEV$_1$ between groups. There was a reduction in the rate of protocol-defined treatment failure compared to placebo</td>
</tr>
<tr>
<td>Scheerens et al (2014)$^{26}$</td>
<td>Randomized, double-blind, parallel-group</td>
<td>29</td>
<td>Mild asthmatics</td>
<td>Lebrikizumab 5 mg/kg SQ monthly for 4 months or placebo</td>
<td>Overall, there was no significant reduction in the LAR. Patients with a Th2 inflammatory profile had a greater reduction in LAR</td>
</tr>
<tr>
<td>Hanania et al (2014)$^{29}$</td>
<td>Two replicate studies, randomized, double-blind, multicenter</td>
<td>463</td>
<td>Uncontrolled asthmatics despite ICS and a second controller</td>
<td>Lebrikizumab 37.5 mg, 125 mg, 250 mg, or placebo SQ monthly for an average of 6 months</td>
<td>Treatment reduced the exacerbation rate and increased FEV$_1$, particularly in those with high periostin levels</td>
</tr>
</tbody>
</table>

**Abbreviations:** FEV$_1$, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long-acting beta-agonist; LAR, late asthmatic response; SQ, subcutaneous; Th2, T helper cell type 2.
Similarly, preliminary results reported by the investigators of the VERSE and LUTE trials demonstrated that lebrikizumab has greater effect in patients with high IL-13 activity. These two replicate studies were performed in a multicenter, double-blind, randomized fashion in uncontrolled asthmatics despite therapy with ICS and a second controller. The combined studies compared placebo to varying doses of lebrikizumab (37.5 mg, 125 mg, or 250 mg) in 463 patients at a ratio of 1:1:1:1. Compared to the placebo group, patients receiving lebrikizumab had greater improvement in FEV₁ and lower exacerbation rates, but the effect was most pronounced in those with high periostin levels.

Why is lebrikizumab not effective in all patients? Asthma is a heterogeneous disease where the Th2 phenotype is only one major pathway involved in pathogenesis. This is one of the major drawbacks of biologics-based therapies; they target a very specific cytokine/component of the inflammatory cascade in asthma. It is clear that many other cytokines and inflammatory pathways other than those mediated by IL-13 are involved in allergic and other forms of asthma. Further, compliance and cost may be prohibitive for some patients. In the case of lebrikizumab, the IL-13 pathway may be only partially activated or not activated at all in mild asthmatics, potentially explaining the lack of response in this subset of patients. Steroid resistance may also play a role in patients with inadequately controlled asthma despite ICS therapy, with the IL-13 pathway not completely inhibited. Therefore, it is plausible that in these steroid-insensitive patients, the blockage of IL-13 may be substantially more beneficial. Which patients would potentially benefit clinically from lebrikizumab based on the available data? This medication has not been approved for clinical use yet, but patients who theoretically would benefit could be those who have uncontrolled asthma despite ICS and LABA use and with a Th2-driven inflammatory pattern, as determined by biomarkers (ie, high levels of periostin, eosinophils, FeNO, and/or IgE).

**Safety**

Lebrikizumab appears to be a safe therapy. The reported rates of adverse reactions are similar compared to placebo, with the exception of an increase in the incidence of musculoskeletal events. Potential adverse effects of biologics in general include injection site reactions, hypersensitivity reactions, infection, and malignancy. Although there has been no safety signal suggesting increased rates of these outcomes associated with lebrikizumab treatment in published data to date, studies of efficacy and safety are currently ongoing.

**Other IL-13 inhibitors**

Tralokinumab is a humanized monoclonal antibody that targets IL-13. This agent was evaluated in a Phase-II, double-blind, placebo-controlled, randomized study that included 194 moderate-to-severe uncontrolled asthmatics. This Phase II study found modest improvement in lung function and a reduction in beta agonist use, and a Phase III development program for tralokinumab in asthma is currently under way. IL-13 has also been identified as a key inflammatory cytokine in ulcerative colitis (UC). A study using tralokinumab in patients with UC failed to show an improvement in clinical response, but there was evidence of superior remission rates. Future studies on the applications of tralokinumab on asthma and UC are needed.

Anrukinumab, a monoclonal antibody to IL-13, blocks the interaction of IL-13 with the IL-4α receptor, thus halting the IL-13-driven inflammatory response. Preliminary pharmacokinetic studies have been performed in patients with asthma and UC, and further studies of safety and efficacy are currently ongoing.

GSK679586, a humanized monoclonal antibody that inhibits IL-13 activity by targeting the α1 and α2 subunits of the IL-13 receptors, has been studied in severe asthma. In a study of 237 patients with asthma refractory to maximal doses of ICS, no differences in Asthma Control Questionnaire symptom scores, FEV₁, or exacerbation rates were seen in GSK679586-treated subjects vs placebo. A subgroup analysis did not detect differences in outcomes in patients with high eosinophil counts or IgE levels. Periostin was not measured as an indicator of IL-13 activity in these studies. A lack of improved asthma outcomes with GSK679586 compared with other inhibitors of IL-13 may be related to differences in potency, blunting of identification of effect in the presence of other treatments, high IL-4 activity, or other unknown mechanisms.

**IL-4/IL-13 inhibitors**

Early attempts to develop cytokine therapies for asthma focused on antagonizing key Th2 cytokines such as IL-4 by blocking the cytokine directly or by blocking its receptor. Although initial preclinical studies of anti-IL4 therapies seemed promising, subsequent human studies surprisingly were unsuccessful. More recently, dupilumab, a fully human monoclonal antibody to the alpha subunit of the IL-4 receptor and that blocks the effects of both IL-4 and IL-13, is under investigation for treatment of Th2 inflammatory disease, including atopic dermatitis and asthma. In a unique study design, patients with moderate-to-severe asthma and
either peripheral blood eosinophil count of \( \geq 300 \) cells/µL or at least 3% sputum eosinophils were randomized to dupilimab or placebo (n=52 in each group).\(^4\) Participants then underwent structured tapering of their standard controllers, first with discontinuation of their LABA and then stepwise reduction of their ICS. The primary end point of asthma exacerbation was observed in three patients treated with dupilimab (6%) vs 23 receiving placebo (44%), an 87% reduction in exacerbations over the 12-week treatment period (odds ratio: 0.08; 95% confidence interval: 0.02–0.28; \( P<0.001 \)). Although these results appear dramatic, only 20% of patients screened for the study were eligible based on the criteria for eosinophilic asthma; thus, the efficacy may only apply to a limited population of patients. Moreover, at least during the brief run-in period, there was no difference in exacerbation rates prior to standard therapy withdrawal. The treatment withdrawal design, while excellent for proof of concept of efficacy, did not demonstrate efficacy of the drug as it would likely be used, as an add-on treatment for those not controlled on standard therapies. Another dual IL-4/IL-13 antagonist, Pitrakinra, has been investigated as both a subcutaneous and inhaled treatment. It has been shown to diminish both the early and late allergic responses and reduce exacerbations of eosinophilic asthma, but it did not show efficacy in a general population of patients with asthma.\(^43,44\)

**Future directions**

There is great interest in the potential benefits of lebrikizumab in the treatment of patients with asthma not controlled with the currently available therapies. There are two ongoing placebo-controlled studies that will explore the efficacy of lebrikizumab despite daily treatment with ICS therapy and at least one additional controller medication in two different asthma populations (NCT01868061, NCT01875003). Another study will compare lebrikizumab vs placebo vs montelukast (1:1:1 ratio) for the therapy of mild-to-moderate asthmatics who are receiving treatment with short-acting beta-agonist alone (NCT02104674). Lastly, an ongoing study will evaluate the use of lebrikizumab in patients with severe asthma who depend on daily corticosteroid therapy (NCT01987492).

**Conclusion**

Although there are promising results with IL-13 inhibitors in asthma, it is important to put these therapies in perspective. Patients with severe asthma should be always adequately assessed for asthma-mimicking diseases and treated for asthma-aggravating conditions before moving unnecessarily to expensive biologics-based therapies, especially in the primary care setting were these might not be available. Additionally, asthma education, trigger avoidance, and medication compliance should be addressed thoroughly. Despite these measures, a significant subset of patients with asthma are either not controlled with high-dose ICS and LABA or require chronic oral steroids for disease control, putting them at risk of significant long-term adverse health effects. Although patients with asthma and Th2 inflammation who are uncontrolled with current standard treatments represent a small segment of the total population of patients with asthma, as one of the most common chronic conditions, a large population of patients who are significantly impaired or are experiencing adverse effects of systemic steroids stand to potentially benefit from anti-IL13 if ongoing studies provide further support of safety and efficacy.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


